Blizzard, McCarthy & Nabers, one of the nation's leading pharmaceutical litigation firms is proud to announce the launch of ReglanJustice.com, an educational website aimed at informing consumers of the risks associated with the use of the drug Reglan, and its generic form, metoclopramide. As a resource for the millions of Americans who use this drug, ReglanJustice.com is regularly updated with the latest news and medical information surrounding the medication and its causal link to debilitative movement disorders.
Long-term use of Reglan and generic forms of metoclopramide has been linked to Tardive Dyskinesia, a serious involuntary and repetitive movement disorder that is often irreversible. A recent study cited by the FDA, reports the prevalence of Tardive Dyskinesia at 20 percent among patients treated with Reglan for at least 12 weeks. In February 2009, the FDA issued a Black Box warning against continued use of Reglan to treat gastrointestinal disorders.
ReglanJustice.com is meant to provide consumers with the critical information denied to them by the pharmaceutical manufacturers marketing these drugs. For those consumers who have already been disabled by these products, ReglanJustice.com provides an avenue to seek legal redress. Corporations that operate with an eye on the bottom line rather than the safety of their consumers must be held accountable for their actions.
"As attorneys, we've seen first hand the damage that can be done by these powerful and dangerous drugs," said Scott Nabers, partner at Blizzard, McCarthy & Nabers. "Consumers were misinformed about the risks associated with this product and many have been permanently disabled. It is our hope that this website will provide consumers with critical information so that future patients can avoid these troubling side effects."
Blizzard, McCarthy & Nabers, LLP, one of the nation's leading pharmaceutical litigation firms, represents thousands of clients harmed by dangerous drugs and medical devices and has taken on some of the world's largest corporations, including Bristol-Myers, GlaxoSmithKline, Merck, Pfizer and Dow Chemical.